Update: AHS leadership has made the difficult yet necessary decision to conduct the 63rd Annual Scientific Meeting virtually. The virtual meeting starts June 3, 2021 and will feature live-streamed sessions, live Q&A and pre-recorded lectures available on demand. For additional details, please view the meeting FAQ here.
WHO SHOULD ATTEND?
The Annual Scientific Meeting is designed for physicians, psychologists, scientists, researchers, physician assistants, nurse practitioners, and other health professionals involved in the care of patients with head, neck, and orofacial pain.
AHS has dedicated over 60 years to leading and serving the headache community.
THE AMERICAN HEADACHE SOCIETY’S® ANNUAL SCIENTIFIC MEETING continues to be the premiere venue for the dissemination of the latest and most up-to-date research and scientific advances underlying the practice of Headache Medicine.
SPECIAL NOTE FOR THE PHYSICALLY CHALLENGED
The American Headache Society® wishes to take steps to ensure that no individual with disability is excluded, denied services, segregated, or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you need any auxiliary aids or services identified in the Americans with Disabilities Act, or any assistance in registering for this symposium, please contact AHS Meeting Manager, Heidi Jetter at 856-423-0043, write to her at AHS, 19 Mantua Road, Mt. Royal, NJ, 08061, or email AHSHQ@talley.com.
SCIENTIFIC PROGRAM COMMITTEE
Chair
Amynah Pradhan, PhD
Members
Jessica Ailani, MD, FAHS
Mark J. Burish, MD, PhD
Catherine D. Chong, PhD, FAHS
Deborah I. Friedman, MD, MPH, FAHS
Todd J. Schwedt, MD, MSCI, FAHS
Elizabeth Seng, PhD, FAHS
Christina L. Szperka, MD, FAHS
PURPOSE/OBJECTIVE
At the conclusion of this meeting, attendees should be better able to:
- Explain fundamental mechanisms of headache disorders and how they relate to new therapies
- Apply an understanding of established and newly introduced therapies to clinical practice
- Become aware of how headache disorders affect cognitive function
- Identify the role of sex and gender in headache disorders
ACCREDITATION STATEMENT
The American Headache Society® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The American Headache Society® designates this Other activity (live and recorded content) for a maximum of 30.00 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS FOR CLAIMING CME
- Attend sessions for which credit is sought in full (this includes watching on-demand courses).
- Complete the post-activity evaluation.
- A certificate of completion will be available once the evaluation is submitted.
FINANCIAL DISCLOSURES
The planners and faculty for this activity did not have any relationships to disclose unless listed here. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.
DISCLOSURE OF COMMERCIAL SUPPORT
The American Headache Society® received funding to support this activity from the following organizations:
AbbVie Inc.
Lilly USA, LLC
Lundbeck LLC
2021 Virtual Annual Scientific Meeting Preliminary Program Agenda*
*All presentation titles and times are tentative and subject to change. Please plan to log in 10 minutes ahead of each start time to hear important welcome announcements.
For a complete list of on demand poster presentations, please click here.
| Thursday, June 3, 2021 | 10:00 am – 2:00 pm EDT Live Session with Q&A |
| Hot Topics in Basic Science Symposium – Part 1
Moderators: Rami Burstein, PhD, Harvard Medical School and Amynah Pradhan, PhD, University of Illinois at Chicago |
| 10:00 AM – 10:20 AM
Interrogating CNS Circuits in Headache and Pain Relief K.C. Brennan, MD, FAHS, University of Utah |
| 10:20 AM – 10:25 AM
Q&A |
| 10:25 AM – 10:45 AM
Translational Significance of the Nitroglycerin Model Peter J. Goadsby, MD, PhD, FAHS, UCLA |
| 10:45 AM – 10:50 AM
Q&A |
| 10:50 AM – 11:10 AM
Modulation of Inhibitory Descending Pain Pathway: Insights into Migraine Pathology and Treatment Paul Durham, PhD, Missouri State University |
| 11:10 AM – 10:15 AM
Q&A |
| 11:15 AM – 11:30 AM
Break |
| Hot Topics in Basic Science Symposium – Part 2
Moderators: Rami Burstein, PhD, Harvard Medical School and Amynah Pradhan, PhD, University of Illinois at Chicago |
| 11:30 AM – 11:50 AM
Imaging Migraine Progression Catherine Chong, PhD, FAHS, Mayo Clinic |
| 11:50 AM – 11:55 AM
Q&A |
| 11:55 AM – 12:15 PM
Sexual Dymorphism in Post-Traumatic Headache Dan Levy, PhD, MSc, BIDMC |
| 12:15 PM – 12:20 PM
Q&A |
| 12:20 PM – 12:40 PM
Voltage Gated Calcium Channels in Migraine Yu-Qing Cao, PhD, Washington University Pain Center |
| 12:40 PM – 12:45 PM
Q&A |
| 12:45 PM – 1:00 PM
Q&A including Part 1 and Part 2 Panelists |
| 1:00 PM – 1:10 PM
Break |
| Data Blitz |
| 1:10 PM – 1:15 PM
CGRP Antibody Rescues Tactile Sensitization Induced by Mild Traumatic Brain Injury in Mice Anne-Sophie Wattiez, PhD, University of Iowa |
| 1:15 PM – 1:20 PM
Perivascular CGRP Actions in a Mouse Model of Migraine Louis K. Balcziak, BA, University of Iowa |
| 1:20 PM – 1:25 PM
Plasma Lipolysis and Desaturase Activity Contribute to Chronic Migraine Pathology Alfred N. Fonteh, PhD, Huntington Medical Research Institutes |
| 1:25 PM – 1:30 PM
Characterization of Cerebrospinal Fluid Phospholipase A2 Isoforms That Increase in Episodic Migraine Alfred N. Fonteh, PhD, Huntington Medical Research Institutes |
| 1:30 PM – 1:35 PM
Non-steroidal Anti-inflammatory Drugs Attenuate Plasma Lipolysis in Chronic Migraine Alfred N. Fonteh, PhD, Huntington Medical Research Institutes |
| 1:35 PM – 1:40 PM
Evaluation of Novel Non-opioid, Non-addictive Therapeutics in the NINDS HEAL Initiative Preclinical Screening Platform for Pain Smriti Iyengar, PhD, NINDS/NIH |
| 1:40 PM – 2:00 PM
Panel Discussion including Data Blitz Panelists/Q&A/Closing Remarks |
|
Friday, June 4, 2021 | 10:00 am – 1:35 pm EDT |
| Keynote Presentations |
| 10:00 AM – 10:30 AM
Genes, Stress and Resilience Huda Akil, PhD, University of Michigan |
| 10:30 AM – 11:00 AM
Diversity and Inclusion: How We Can Learn from Others to Improve Diversity in Headache Research Richard Benson, MD, PhD, NINDS/NIH |
| 11:00 AM – 11:15 AM
Q&A |
| 11:15 AM – 11:25 AM
Break |
| Plenary I: Hot Topics in Headache |
| 11:25 AM – 11:40 AM
Role of CGRP in Infection-induced Pain Isaac M. Chiu, PhD, Harvard University |
| 11:40 AM – 11:55 AM
Vaccines and Their Impact on Migraine Treatment Amy A. Gelfand, MD, FAHS, UCSF Weill Institute for Neurosciences |
| Debate: Should ICHD Maintain Chronic Migraine as a Separate Diagnosis from Migraine |
| 12:10 PM – 12:30 PM
Pro David W. Dodick, MD, FAHS, Mayo Clinic Con Andrew D. Hershey, MD, PhD, FAHS, Cincinnati Children’s Hospital Medical Center |
| 12:30 PM – 12:40 PM
Rebuttal |
| 12:40 PM – 12:50 PM
Break |
| Debate: The ICHD-3 Criteria for TTHA Should be Changed |
| 12:50 PM – 1:10 PM
Pro Deborah I. Friedman, MD, MPH, FAHS, UT Southwestern Medical Center Con Morris Levin, MD, FAHS, UCSF Headache Center |
| 1:10 PM – 1:20 PM
Rebuttal |
| 1:20 PM – 1:35 PM
Closing Remarks |
| 2:00 PM – 3:00 PM
Talent Show |
|
Saturday, June 5, 2021 | 10:00 am – 1:40 pm EDT |
| Plenary II: Thinking Through the Pain of Migraine: Cognitive Findings, Neuroimaging and Behavioral Strategies
Moderators: Elizabeth Seng, PhD, FAHS, Yeshiva University/Albert Einstein College of Medicine and Alexandra C. Ross, PhD, University of California San Francisco |
| 10:00 AM – 10:20 AM
Cognition and Pain Processing Tim Salomons, PhD, Queens University |
| 10:20 AM – 10:40 AM
Cognitive Dysfunction and Migraine Raquel Gil-Gouveia, MD, PhD, Hospital de Luz |
| 10:40 AM – 11:00 AM
Cognitive Strategies and Migraine David Seminowicz, PhD, University of Maryland |
| 11:00 AM – 11:15 AM
Q&A |
| 11:15 AM – 11:30 AM
Break |
| Plenary III: Cortical Spreading Depression and Headache
Moderators: Catherine D. Chong, PhD, FAHS, Mayo Clinic and Amynah Pradhan, PhD, University of Illinois at Chicago |
| 11:30 AM – 11:50 AM
Relationship Between CSD and Sleep Andrew Charles, MD, FAHS, University of California, Los Angeles |
| 11:50 AM – 12:10 PM
CSD Can Evoke Anxiety and Pain Andrea Harriott, MD, PhD, Massachusetts General Hospital |
| 12:10 PM – 12:30 PM
CSD Evocation (Clinical base) Messoud Ashina, MD, PhD, Glostrup Hospital |
| 12:30 PM – 12:45 PM
Q&A |
| 12:45 PM – 12:55 PM
Break |
| Harold G. Wolff Award Lecture |
| 12:55 PM – 1:10 PM
Chronic versus Episodic Migraine: The 15-day Threshold Does Not Adequately Reflect Substantial Differences in Disability Across the Full Spectrum of Headache Frequency Ryotaro Ishii, MD, PhD, Mayo Clinic |
| 1:10 – 1:25 PM
Q&A |
| 1:25 PM – 1:40 PM
Closing Remarks |
| 2:00 PM – 3:00 PM
Membership Meeting* *All registered AHS members have been pre-registered for the webinar. A link will be sent separately to access this event. |
|
Sunday, June 6, 2021 | 10:00 am – 12:10 pm EDT |
| Plenary IV: Sex, Gender Specific Differences in Headache |
| 10:00 AM – 10:20 AM
Sex Differences in Pain: From Nociceptor to Brain Gregory Dussor, PhD, University of Texas at Dallas |
| 10:20 AM – 10:40 AM
Does Sex/Gender Impact the Brain’s Activation Patterns in Pain? Nasim Maleki, PhD, Harvard Medical School |
| 10:40 AM – 11:00 AM
Does Gender Impact the Presentation of Headache Disorders, Response to Treatment, and Adherence; Learnings from Clinic Anna Pace, MD, Mt. Sinai Hospital |
| 11:00 AM – 11:15 AM
Q&A |
| 11:15 AM – 11:25 AM
Break |
| Early Career Award Lecture |
| 11:25 AM – 11:40 AM
Learning the Full Impact of Migraine Through Patient Voices: Results of a Qualitative Study Rebecca Erwin Wells, MD, MPH, FAHS, Wake Forest University Baptist Medical Center |
| 11:40 AM – 11:55 AM
Q&A |
| 11:55 AM – 12:10 PM
Closing Remarks |
|
On-Demand Content For a complete list of on demand poster presentations, please click here. |
| Special Interest Section Symposium |
| Life in a Pandemic- A Window into the Life of a Person with Migraine
Presented by Migraine and Women’s Health Section |
| Window into the Life of a Person with Migraine- using the Pandemic to Highlight the Social Isolation of a Person with Chronic Migraine
Deena E. Kuruvilla, MD, FAHS, Westport Headache Institute |
| Direct From the Patient; The Lived Experience of Migraine During the Global Pandemic
Dawn C. Buse, PhD, FAHS, Albert Einstein College of Medicine |
| The Legal Aspects of Dealing with Migraine – Workplace Issues
Nina Riggins, MD, PhD, University of California, San Francisco |
| Caring for Migraine Patients Amidst a Global Pandemic – A Provider Perspective
Carolyn Bernstein, MD, FAHS, Harvard Medical School |
| A Pain in the Neck: Interventional and Physical Therapy Approaches to Neck Pain in Adult and Pediatric Populations with Headache and Temporomandibular Disorders
Presented by Procedural Headache Medicine Section, TMD, Cervical Spine, and Orofacial Pain Section |
| Interventional Approaches to Headache with Associated Neck Pain
Jason W. Siefferman, MD, Manhattan Pain Medicine, PLLC |
| Management of Pediatric Headache with Associated Neck Pain
Chaouki Khoury, MD, MS, FAHS, Atlanta Headache Specialists |
| The Relationship of TMD with Cervical Pain and Headache Disorders
Antonia Teruel, DMD, MS, PhD, Head Pain Institute |
| Physical Therapy Modalities for the Treatment of Headache, Neck Pain, and Temporomandibular Disorders
Danielle Messier, MSPT, DPT, Cert MDT, Hartford Healthcare Rehabilitation Network |
| Interpreting Current Evidence on Diet and Physical Activity in Migraine for Clinical Practice
Presented by Behavioral Issues, Co-sponsored by the Methodology, Design, and Statistical Issues Section and the Complementary and Integrative Medicine Section |
| Physiological Mechanisms by Which Exercise Influences Migraine
Megan Irby, PhD, Wake Forest Baptist Medical Center |
| Move More, Sit Less: Managing Migraine by Making Physical Activity a Part of Daily Life
Dale S. Bond, PhD, The Miriam Hospital/Brown Alpert Medical School Weight Control and Diabetes Research Center |
| Dietary Considerations for Migraine
Margaret Slavin, PhD, RDN, George Mason University |
| Health Equity and Inclusion in Headache Medicine
Presented by New Investigators and Trainees Section & Underserved Population Section |
| A Population Health Approach to Migraine
Joanna Kempner, PhD, Rutgers University |
| Structural Competency and Headache: Observations from a Bronx Academic Center
Cynthia E. Armand, MD, Albert Einstein College of Medicine |
| Providing Care to Rural Native Americans
Michael Stitzser, MD, Winsow Indian Heath Care Center |
| Reaching Out: Treating Underserved Populations
Charles C. Flippen II, MD, David Geffen School of Medicine at UCLA |
| The Headache Pipeline
Larry Charleston IV, MD, MSc, FAHS, Michigan State University |
| Research and Underserved Populations
Megan Irby, PhD, Wake Forest Baptist Medical Center |
| Scientific Abstract Presentations |
| Amylin Induces Migraine-Like Behaviors in Mice
Levi P. Sowers, PhD, University of Iowa |
| Neuronal Complexity Is Attenuated in Chronic Migraine and Restored by HDAC6 Inhibition
Zachariah J. Bertels, PhD, University of Illinois at Chicago |
| Analyzing Serum CGRP Levels and Inflammatory Markers in Chronic Migraine in Comparison to Episodic Migraine and Healthy State
Mansoureh Togha, Tehran University of Medical Sciences |
| PACAP-induced Cephalic Allodynia Is Inhibited by Delta Opioid Receptor Activation
Elizaveta Mangutov, BS, University of Illinois at Chicago |
| Transient Blood Brain Barrier Opening During Cortical Spreading Depression Results from Dynamic Reorganization of the Tight Junction Protein Claudin 5
Jared Wahl, MPH, University of Arizona |
| The Role of Cerebellar CGRP in Migraine-like Behavior
Mengya Wang, University of Iowa |
| Links Between Functional NHE1 Expression at the Blood Brain Barrier, HSP90 and Sumatriptan Blood to Brain Uptake
Seph Palomino, BS, University of Arizona |
| Transcriptional and Epigenomic Comparison of Human and Mouse Trigeminal Ganglia at Single-cell Resolution
Lite Yang, BS, Brigham and Women’s Hospital |
| Spatial Aspects of Pain Modulation in Adolescents with Migraine
Hadas Nahman-Averbuch, PhD, Cincinnati Children’s Hospital |
| Impact of Abuse on Migraine Hypersensitivity Symptoms: Results from the American Registry for Migraine Research (ARMR)
Meesha Trivedi, BS, Mayo Clinic |
| Reasons for Hesitating to Consult for Migraine Care: Results of the OVERCOME (US) Study
Robert E. Shapiro, MD, PhD, Larner College of Medicine, University of Vermont |
| Characterizing Preventive Treatment Gaps in Migraine: Results from the CaMEO Study
Stephanie J. Nahas, MD, MDEd, Thomas Jefferson University |
| Suicide Attempt Incidence and Psychiatric Comorbidities in Veterans with Chronic Head, Neck and Back Pain from 2001-2010: Trends and Associations
X. Michelle Androulakis, MD, FAHS, University of South Carolina |
| Pediatric Ischemic Stroke and Migraine: The Conundrum of Association!
Anna McDonnell, University of Mississippi Medical Center |
| Patient Experience of Telemedicine for Headache Care During the COVID-19 Pandemic: An American Migraine Foundation Survey Study
Chia-Chun Chiang, MD, Mayo Clinic |
| Assessment of Cognitive Interference in Migraine: Results of the MiCOAS Qualitative Study
Maya Gerstein, DrPH, PHarmerit – An Open Health Company |
| Is Post-Traumatic Headache in Veterans Different Than Traumatic Brain Injury with Headache?
John Ney, MD, MPH, VA Connecticut Healthcare System, Headache Centers of Excellence Research & Evaluation Center |
| Differentiating Between Migraine and Post-traumatic Headache with a Machine Learning Classifier
Gina Dumkrieger, PhD, Mayo Clinic |
| White Matter Hyperintensities in Patients with Migraine
Catherine Chong, PhD, Mayo Clinic |
| Central Sensitization and Migraine Treatments Impact on Thalamic Metabolism: MR Study at 21.1 T
Samuel Holder, BS, Florida State University |
| Patterns of Medical Cannabis Use and Strain Analysis Among Patients with Migraine and Headache in a Medical Cannabis Cohort; A Follow-Up Study
Eric P. Baron, DO, Cleveland Clinic |
| A Survey of the Most Common Drugs Causing Headaches in FDA Adverse Event Reporting System
Brett Musialowicz, BA, Rutgers Robert Wood Johnson Medical School |
| Estimating the Probability of Reported versus Theoretical Drug-Drug Interactions in Headaches Medicine
Victor Kaytser, MD, Rutgers Robert Wood Johnson Medical School |
| Effectiveness of Mindfulness Meditation vs. Headache Education for Adults with Migraine: A Randomized Clinical Trial
Rebecca E. Wells, MD, MPH, FAHS, Wake Forest School of Medicine |
| Industry-submitted Abstract Presentations |
| Effect of Galcanezumab on Migraine Headache Days in Women with Menstrual Migraine: A Post Hoc Analysis
E. Anne MacGregor, MBBS, MSc, MD, St. Bartholomew’s Hospital |
| A Phase 3 Randomized, Double-blind, Sham-controlled Trial of e-TNS for the Acute Treatment of Migraine (TEAM)
Deena E. Kuruvilla, MD, VA Connecticut Healthcare System, Headache Centers of Excellence Research & Evaluation Center |
| A Phase 2 Study of Fremanezumab as a Treatment for Posttraumatic Headache in Adult Patients
Egilius L.H. Spierings, MD, PhD, Medvadis Research Corporation |
| Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the INTERCEPT Phase 3 Randomized, Double-blind, Placebo-controlled Trial
Amanda Jones, PharmD, Axsome Therapeutics Inc. |
| Noninvasive Combined Occipital and Trigeminal Nerve Stimulation for Treatment of Migraine – a Multi-Center, Randomized, Sham-Controlled Pivotal Study
Stewart J. Tepper, MD, FAHS, Geisel School of Medicine at Dartmouth |
| Real-World Evidence for Control of Patients with Chronic Migraine Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
Andrew Blumenfeld, MD, Headache Center of Southern California |
| Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine
Jessica Ailani Risk of Hypertension in Erenumab-treated Patients with Migraine in Clinical Trials and in the Postmarketing Setting David W. Dodick, MD, FAHS, Mayo Clinic |
| Rapid Resolution of Migraine Symptoms After Initiating the Preventive Treatment Eptinezumab During a Migraine Attack
Jessica Ailani, MD, FAHS, MedStar Georgetown University Hospital |
| Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence
Richard B. Lipton, MD, FAHS, Albert Einstein College of Medicine |
| Intranasal Zavegepant Is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical Trial
Robert Croop, MD, Biohaven Pharmaceuticals, Inc. |
| A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Robert Croop, MD, Biohaven Pharmaceuticals, Inc. |
| Late-breaking Abstract Presentations |
| Migraine Is Associated With Higher Incidence of COVID-19, and Higher Frequency of COVID-19 Symptoms, but Lower COVID-19-Associated Health Care Resource Utilization Rates
Robert E. Shapiro, MD, PhD, FAHS, University of Vermont |
| Pediatric Headache Experience During the COVID-19 Pandemic
Marc DiSabella, DO, Children’s National Medical Center |
| NIH Roadmap for Migraine Research Update |
| NIH Roadmap for Migraine Research Update
Michael L. Oshinsky, PhD, The National Institute of Neurological Disorders and Stroke |
| Seymour Solomon Award Lecture |
| What Is…”Getting Better?”
Scott W. Powers, PhD, ABPP, FAHS |
| John R. Graham Award Lecture |
| Practicing Headache Medicine in 2021: Realities on the Ground
Deborah I. Friedman, MD, MPH, FAHS |
| Future of Headache Medicine Presentations |
| Disconnectome of the Migraine Brain: A Model of Migraine as “connectopathy”
Marcello Silvestro, MD, University of Campania “Luigi Vanvitelli” |
| Simultaneous Comparisons of 22 Acute Migraine Medications: A Big Data Analysis of 10 Million Patient Self-reported Treatment Records from a Migraine Smartphone Application
Xuemin Fang, PhD, Graduate School of Health Innovation/Kanagawa University of Human Services |
| International Headache Academy Research Award Presentations |
| Visual Evoked Potentials as a Biomarker for Persistent Post-traumatic Headache
Carlyn A. Patterson Gentile, MD, PhD, Children’s Hospital of Philadelphia |
| How Does Headache Treatment Help? Identification of Patient-valued Outcome Measures in Adolescents with Continuous Headache
Kaitlin A. Greene, MD, Oregon Health & Science University |
| Data Cartography to Understand Local, Regional and Provincial Patterns of Headache Diagnosis, Treatment and Health Resource Utilization in Alberta, Canada
Thilinie Rajapakse, MD, FRCPC, University of Alberta/Stollery Children’s Hospital |
| Characterization of Molecular Adaptations Within Trigeminal Dural Afferents in Response to Head Pain
William Renthal, MD, PhD, Harvard Medical School |
| Frontiers in Headache Research Award Platform Presentations |
| Self-Administered At-Home Sphenopalatine Ganglion (SPG) Blockade for the Prevention and Acute Treatment of Migraine
Sarah Bobker, MD, USCF Headache Center |
| The Probability of Atrial Fibrillation Predicted by an AI-enabled ECG Algorithm in Patients with Migraine with Aura and Migraine without Aura
Nikita Chhabra, DO, Mayo Clinic |
| Relationship between Intervals of the Menstrual Cycle and Presentation to the Emergency Department for Headache
Crystal Jicha, MD, Montefiore Medical Center |
| Frontiers in Headache Research Award Poster Presentations |
| Is Attribution of Blame in Concussion Linked to Post-traumatic Headache?
Caitlin Christensen, MD, University of Alberta |
| Addressing Mental Health Among Patients with Chronic Headaches to Improve Outcomes, Wellbeing, and Resource Utilization
Kelsey Duncan, MD, Case Western Reserve University/University Hospitals Cleveland Medical Center |
| Joint Hypermobility Syndrome in Children and Adolescents with Headaches: Retrospective Study
Ankita Ghosh, MD, Cincinnati Children’s Hospital Medical Center |
| Migraine in Women Undergoing Fertility Treatment: A Prospective Study
Jasmin Harpe, MD, NewYork-Presbyterian Hospital |
| Diagnostic Delay of Chronic Migraine and Medication Overuse Headache at a Tertiary Care Center in Peru
Farrah Khan, MD, University of Washington |
| Predictors of Clinical Response to Erenumab in Patients with Migraine
Olga Lekontseva, MD, PhD, University of Calgary |
| Nerve Blocks for the Treatment of COVID-19 Related Headache
Aarushi Suneja, MD, Cleveland Clinic |
| 6th Annual Migraine Moment Short Film Contest Video Viewing
Migraine: The Invisible Illness That Alters the Lives of Millions Morgan Fitzgerald |
| Headache Lounges |
| Thursday, June 3, 2021 2:00 – 3:00 PM EDT Basic Science Headache Lounge Moderators: Gregory Dussor, PhD and Hadas Nahman-Averbuch, PhD |
| Friday, June 4, 2021 3:15 – 4:15 PM EDT New Member Headache Lounge Moderators: Matthew S. Robbins, MD, FAHS and Jaclyn R. Duvall, MD |
| Saturday, June 5, 2021 3:15 – 4:15 PM EDT Clinical Headache Lounge Moderator: Jessica Ailani, MD, FAHS |
2021 Virtual Annual Scientific Meeting Registration Fees and Information
Online registration is now open. Click here to register.
AHS Member and Non-member Registration Categories and Fees
| AHS MEMBER | FEE |
| Active Member (MD, DO, PhD, DDS) | $300.00 |
| Associate Member (RN, NP, PA) | $150.00 |
| Trainee Member | $75.00 |
| NON-MEMBER | FEE |
| Non-Member (MD, DO, PhD, DDS) | $450.00 |
| Non-Member Associate (RN, NP, PA) | $200.00 |
| Non-Member Trainee | $125.00 |
| OTHER | FEE |
| Active Military Personnel | $75.00 |
| Industry Representative | $450.00 |
Registration Information
Instructions will be sent to the email address provided during registration prior to the anticipated launch date of Thursday, June 3, 2021.
Acceptable Forms of Payment
Credit cards may be used for all registrations. AHS accepts Visa, MasterCard, and American Express. Charges will appear on your statement as “AHS Registration.”
Exhibit and Sponsorship Information
The Exhibit and Sponsorship portal will allow you to select a sponsorship opportunity (virtual booth included) or purchase a virtual exhibit booth without sponsorship. You will also be able to upload your logo, booth materials, video chat with meeting attendees and much more.
To access the portal, please click here and create an account (click to start button) for the 2021 Virtual Annual Scientific Meeting.
Based on your feedback we are pleased to announce several new features including the availability of a 3D virtual exhibit booth. Additionally, below you will find a summary of the enhancements that we hope you find beneficial for your virtual expo experience:
- *NEW* 3D Booth – customizable to provide promotional elements and information to attendees.
- Banner Advertisement – will appear at the top of the virtual booth and can link to an external URL.
- Video link – a video that provides a short synopsis of your company’s mission or product.
- Video Chat Room – those with industry roles can connect with AHS attendees via video chat from the virtual booth.
- Enhanced Description – can include logo, extended description.
- Resource Documents (content links / PDF handouts) – provide attendees with material about your company.
- Exhibit Hall gamification – incentivize meeting attendees to visit your booth.
Through your account, you will have access to all up-to-date information regarding the 2021 Virtual Annual Scientific Meeting. You can also submit payments and manage your account settings through the portal.
Please be prepared to answer a few more questions this year. The Exhibit Review Committee has made some changes to the review process for both previous and new exhibitors. For example, if you have a new product or device, and have exhibited in the past, you may be asked to submit additional collateral before receiving final approval to exhibit.
Please click here to view exhibit and sponsorship opportunities for the 2021 Virtual Annual Scientific Meeting.
Industry Supported Events
Industry-supported events, CME or non-CME, will be accessible to all meeting registrants via the virtual meeting site. The deadline to submit requests for Industry-Supported Events has passed.
The American Headache Society gratefully acknowledges the support of the 2021 Virtual Annual Scientific Meeting from our industry supporters:
Platinum
Allergan plc (NYSE: AGN), an AbbVie company (NYSE: ABBV), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. |
In August 2015, Amgen and Novartis entered into a global collaboration to develop and commercialize pioneering treatments in the field of Neuroscience. At the center of the Amgen and Novartis collaboration is the shared mission to fight migraine and the stereotypes and misperceptions surrounding this debilitating disease. |
Lilly was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. |
Lundbeck, a global pharmaceutical company based in Denmark and founded in 1915, is tirelessly dedicated to restoring brain health, so every person can be their best. Lundbeck has a long heritage of innovation in neuroscience and is focused on delivering transformative treatments that address unmet needs in brain health. |
|
Teva Pharmaceuticals is a global leader in generic medicines and biopharmaceuticals. Building on more than a century-old legacy, Teva delivers high-quality products to patients in nearly every therapeutic area, has an established presence in generics, specialty, OTC and API, a fully integrated R&D function, strong operational base and global infrastructure and scale. |
Gold
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company. We offer a suite of branded central nervous system (CNS) medications to help patients living with migraine headaches and seizure disorders. |
Silver
 |
 |
Bronze
| Currax Pharmaceuticals LLC |
| Eli Lilly and Company |
| Impel NeuroPharma |
| Neurolief |
| Theranica Bio-Electronics LTD |
Participating
| Ctrl M Health |
AHS gratefully acknowledges the educational grant support of the 2021 Virtual Annual Scientific Meeting from our industry supporters:
| AbbVie Inc. |
| Amgen Inc. |
| Lilly USA, LLC |
| Lundbeck LLC |
Abstracts
The abstract submission period has passed. Authors will receive acknowledgement of receipt of abstracts via email and notification regarding acceptance on or before May 1, 2021.
Each abstract must include objectives, methods, results and conclusions and is limited to 3300 characters (characters include letters, symbols, punctuation and spaces). Mandatory fields are identified with an (*) in the submission site. If the data submitted has been presented in total or in large part in the past, please note the date and place of the previous presentation(s).
Abstract Topics are as follows:
- Basic Science
- Clinical Presentation/Diagnosis
- Epidemiology
- Genetics
- Headache Education
- Health Services/Outcomes Research
- Imaging and Neurophysiology
- Therapeutics
- Other Clinical Studies
- Other
For questions or additional information, please contact AHS Headquarters at 856-423-0043 or ahshq@talley.com.
Welcome to the American Headache Society’s 2021 Virtual Annual Scientific Meeting Press Room. Here you can find the latest news releases related to this scientific forum, as well as press guidelines for media professionals, exhibitors, presenters and satellite symposia organizers.
All media-related questions, including obtaining press passes, can be directed to Lauren Schoener-Gaynor at lschoener-gaynor@talley.com or 856-905-5211.
“Frontiers in Headache Research” Scholarship Awards
The American Headache Society announces the availability of up to 10 “Frontiers in Headache Research” Scholarship Awards for the Virtual Annual Scientific Meeting scheduled for June 3-6, 2021.
Recipients will receive complimentary meeting registration and a one-year AHS Trainee membership if not already a member of AHS, or a one-year extension of their existing AHS Trainee membership, and be eligible to receive a stipend up to $1,000 for reimbursement of expenses for food, travel and hotel should the meeting remain an in-person event.
Criteria for selection are based on:
- The quality of the research proposal/project
- The potential for the proposal, study or thesis to contribute to the advancement of knowledge and future research in the field of Headache Medicine
Applicant must:
- Be a Headache Medicine Fellow, Resident and or post-doctoral fellow who is in preparatory, active or completion phase of a basic or clinical research project that is related to headache or cranial nociception
- Not have won an AHS scholarship within the past 2 years. Past winners within 2 years are not eligible to apply
- Reside in the United States or Canada
Recipient requirements:
- The top three selected will be required to present their proposal or results to attendees at the 63rd Annual Scientific Meeting
- All other recipients will be required to submit a poster for display at the 63rd Annual Scientific Meeting
Thank you for your interest in applying for a “Frontiers in Headache Research” Scholarship Award. The application period has closed and recipients will be notified in the coming weeks.
AHS members are invited to participate in Special Interest Section meetings that will be held virtually via Zoom. Please log into your member account and access the event under “My Profile” for Zoom details.
| Date | Time (EDT) | Section |
| Monday, May 10, 2021 | 12:00 – 1:00 pm | Complementary and Integrative Medicine |
| Monday, May 10, 2021 | 7:00 – 8:00 pm | Pediatric-Adolescent Headache |
| Tuesday, May 11, 2021 | 6:00 – 7:00 pm | Clinical Informatics |
| Thursday, May 13, 2021 | 5:00 – 6:00 pm | Women’s Health |
| Thursday, May 13, 2021 | 7:00 – 8:00 pm | Procedural Headache Medicine |
| Friday, May 14, 2021 | 5:00 – 6:00 pm | Refractory, Inpatient and Emergency Care |
| Tuesday, May 18, 2021 | 8:00 – 9:00 pm | Advanced Practice Providers |
| Wednesday, May 19, 2021 | 5:00 – 6:00 pm | Post-traumatic Headache |
| Thursday, May 20, 2021 | 8:00 – 9:00 pm | New Investigators and Trainees |
| Friday, May 21, 2021 | 12:00 – 1:00 pm | Behavioral Issues |
| Monday, May 24, 2021 | 8:00 – 9:00 pm | Methodology, Design, and Statistical Issues |
| Tuesday, May 25, 2021 | 6:00 – 7:00 pm | Underserved Populations in Headache Medicine |
| Tuesday, June 1, 2021 | 7:00 – 8:00 pm | CSF Pressure and Volume Disorders |
| Monday, June 7, 2021 | 6:00 – 7:00 pm | Migraine and Vascular Disorders |
| Wednesday, June 9, 2021 | 7:00 – 8:00 pm | TMD, Cervical Spine & Orofacial Pain |
| Wednesday, June 30, 2021 | 7:00 – 8:00 pm | Primary Front Line Headache Care |